1h Free Analyst Time
SummarySpeak directly to the analyst to clarify any post sales queries you may have.
The latest Pharmaceutical and Healthcare disease pipeline guide Narcolepsy - Pipeline Review, H2 2020, provides an overview of the Narcolepsy (Central Nervous System) pipeline landscape.
Narcolepsy is a sleep disorder that causes excessive sleepiness and frequent daytime sleep attacks. Symptoms of narcolepsy include excessive daytime sleepiness (EDS), cataplexy, hallucinations and sleep paralysis. Narcolepsy treatment includes lifestyle change, medication and counseling.
Report Highlights
The Pharmaceutical and Healthcare latest pipeline guide Narcolepsy - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Narcolepsy (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Narcolepsy (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Narcolepsy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 7, 5, 5 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Narcolepsy (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Narcolepsy (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Narcolepsy (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Narcolepsy (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Narcolepsy (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Narcolepsy (Central Nervous System)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Narcolepsy (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Narcolepsy (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Narcolepsy - Overview
- Narcolepsy - Therapeutics Development
- Narcolepsy - Therapeutics Assessment
- Narcolepsy - Companies Involved in Therapeutics Development
- Narcolepsy - Drug Profiles
- Narcolepsy - Dormant Projects
- Narcolepsy - Discontinued Products
- Narcolepsy - Product Development Milestones
- Appendix
List of Tables
- Number of Products under Development for Narcolepsy, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Products under Development by Companies, H2 2020
- Products under Development by Companies, H2 2020 (Contd..1), H2 2020
- Products under Development by Universities/Institutes, H2 2020
- Number of Products by Stage and Target, H2 2020
- Number of Products by Stage and Mechanism of Action, H2 2020
- Number of Products by Stage and Route of Administration, H2 2020
- Number of Products by Stage and Molecule Type, H2 2020
- Narcolepsy - Pipeline by Avadel Pharmaceuticals Plc, H2 2020
- Narcolepsy - Pipeline by Axsome Therapeutics Inc, H2 2020
- Narcolepsy - Pipeline by Balance Therapeutics Inc, H2 2020
- Narcolepsy - Pipeline by Bioprojet SCR, H2 2020
- Narcolepsy - Pipeline by F. Hoffmann-La Roche Ltd, H2 2020
- Narcolepsy - Pipeline by Inexia Ltd, H2 2020
- Narcolepsy - Pipeline by Jazz Pharmaceuticals Plc, H2 2020
- Narcolepsy - Pipeline by NLS Pharma Group, H2 2020
- Narcolepsy - Pipeline by Ono Pharmaceutical Co Ltd, H2 2020
- Narcolepsy - Pipeline by Orexia Ltd, H2 2020
- Narcolepsy - Pipeline by Seelos Therapeutics, Inc., H2 2020
- Narcolepsy - Pipeline by SK Biopharmaceuticals Co Ltd, H2 2020
- Narcolepsy - Pipeline by Suven Life Sciences Ltd, H2 2020
- Narcolepsy - Pipeline by Takeda Pharmaceutical Co Ltd, H2 2020
- Narcolepsy - Pipeline by Theranexus SAS, H2 2020
- Narcolepsy - Pipeline by Vallon Pharmaceuticals Inc, H2 2020
- Narcolepsy - Pipeline by XWPharma, H2 2020
- Narcolepsy - Dormant Projects, H2 2020
- Narcolepsy - Dormant Projects, H2 2020 (Contd..1), H2 2020
- Narcolepsy - Discontinued Products, H2 2020
List of Figures
- Number of Products under Development for Narcolepsy, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products by Top 10 Targets, H2 2020
- Number of Products by Stage and Top 10 Targets, H2 2020
- Number of Products by Top 10 Mechanism of Actions, H2 2020
- Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
- Number of Products by Routes of Administration, H2 2020
- Number of Products by Stage and Routes of Administration, H2 2020
- Number of Products by Molecule Types, H2 2020
- Number of Products by Stage and Molecule Types, H2 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Avadel Pharmaceuticals Plc
- Axsome Therapeutics Inc
- Balance Therapeutics Inc
- Bioprojet SCR
- F. Hoffmann-La Roche Ltd
- Inexia Ltd
- Jazz Pharmaceuticals Plc
- NLS Pharma Group
- Ono Pharmaceutical Co Ltd
- Orexia Ltd
- Seelos Therapeutics, Inc.
- SK Biopharmaceuticals Co Ltd
- Suven Life Sciences Ltd
- Takeda Pharmaceutical Co Ltd
- Theranexus SAS
- Vallon Pharmaceuticals Inc
- XWPharma
